Related Experiment Video
Updated: Aug 6, 2026
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
PD-1 Inhibition With Camrelizumab in Cervical Cancer: A Systematic Review and Meta-Analysis
Adeena Musheer1, Muhammad S Mannan2, Muhammad W Khan3
1Department of Internal Medicine, Dow Medical College, DUHS, Karachi.
American Journal of Clinical Oncology
|July 22, 2026
Summary
Camrelizumab shows significant antitumor effects in cervical cancer, especially when combined with other treatments. Careful monitoring of side effects like neutropenia and anemia is crucial for patient safety.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Cervical cancer is a major global health concern for women.
- Programmed death-ligand 1 (PD-L1) is frequently expressed in cervical tumors.
- Camrelizumab, an anti-programmed death-1 (PD-1) antibody, exhibits anti-cancer properties.
Purpose of the Study:
- To evaluate the efficacy and safety of camrelizumab in cervical cancer patients.
- To assess response rates and disease control with camrelizumab-based therapies.
- To identify common adverse events associated with camrelizumab treatment.
Main Methods:
- Systematic literature search across major databases (PubMed, Embase, Web of Science, etc.).
- Inclusion of randomized trials, single-arm trials, cohort, and case-control studies.
- Calculation of pooled proportions and heterogeneity assessment using R software.
Main Results:
- Eight studies with 382 patients were analyzed.
- Pooled objective response rate (ORR) was 62%; disease control rate (DCR) was 83%.
- Common adverse events included neutropenia, anemia, and hypertension.
Conclusions:
- Camrelizumab demonstrates clinically significant antitumor activity in cervical cancer.
- Combination regimens involving camrelizumab appear particularly effective.
- Management of treatment-related toxicities is essential for optimal outcomes.
